Related references
Note: Only part of the references are listed.Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells
Tatsunori Suzuki et al.
CANCER GENE THERAPY (2022)
Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy
Winnie Fong et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2021)
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
S. Dent et al.
ANNALS OF ONCOLOGY (2021)
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
Brian D. Lehmann et al.
CLINICAL CANCER RESEARCH (2020)
Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer
Savitha Sridharan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
Eva Schrezenmeier et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
Identification of synergistic drug combinations using breast cancer patient-derived xenografts
Tia H. Turner et al.
SCIENTIFIC REPORTS (2020)
The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells
Jiajing Cai et al.
FEBS OPEN BIO (2020)
Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges
Raymond Chang et al.
DRUG DISCOVERY TODAY (2020)
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
Stefania Cocco et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Targeting Autophagy in Breast Cancer
Stefania Cocco et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
ATG5-mediated autophagy suppresses NF-κB signaling to limit epithelial inflammatory response to kidney injury
Xuan Peng et al.
CELL DEATH & DISEASE (2019)
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer
Javier Cortes et al.
FUTURE ONCOLOGY (2019)
Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
So-Yeon Park et al.
CANCERS (2019)
A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients
Angel Arnaout et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Richard D. Baird et al.
CLINICAL CANCER RESEARCH (2019)
TNeoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Cristina Saura et al.
LANCET ONCOLOGY (2019)
Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
M. Brandao et al.
ANNALS OF ONCOLOGY (2019)
Autophagy promotes triple negative breast cancer metastasis via YAP nuclear localization
Wei Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
Cesar H. Saravia et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2019)
Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells
Zuhal Hamurcu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion
Mario Mauthe et al.
AUTOPHAGY (2018)
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2018)
Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance
Cristina Amaral et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2018)
A Phase Ib Study of Alpelisib (BYL719), a PI3K alpha-Specific Inhibitor, with Letrozole in ER+/HER2(-) Metastatic Breast Cancer
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2017)
Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
Manuela Terranova-Barberio et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Manuela Terranova-Barberio et al.
ONCOTARGET (2017)
High-Content Monitoring of Drug Effects in a 3D Spheroid Model
Frederique Mittler et al.
FRONTIERS IN ONCOLOGY (2017)
Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents
Ciska Verbaanderd et al.
ECANCERMEDICALSCIENCE (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
Zachary S. Zumsteg et al.
CLINICAL CANCER RESEARCH (2016)
Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib
Suning Chen et al.
TUMOR BIOLOGY (2016)
Protein Kinase G facilitates EGFR-mediated cell death in MDA-MB-468 cells
Nicole M. Jackson et al.
EXPERIMENTAL CELL RESEARCH (2016)
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression
Chiara Ciardiello et al.
ONCOTARGET (2016)
ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells
Yaochen Wang et al.
ONCOTARGET (2016)
Reference Intervals for Hemoglobin and Age- and Gender-Related Trends in the Population of Southwest China
Chengjie Ji et al.
CLINICAL LABORATORY (2015)
mTOR: a pharmacologic target for autophagy regulation
Young Chul Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Lauren M. Thorpe et al.
NATURE REVIEWS CANCER (2015)
The fate of chemoresistance in triple negative breast cancer (TNBC)
Elma A. O'Reilly et al.
BBA CLINICAL (2015)
STAT3-Mediated Autophagy Dependence Identifies Subtypes of Breast Cancer Where Autophagy Inhibition Can Be Efficacious
Paola Maycotte et al.
CANCER RESEARCH (2014)
Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma
Bo Zhai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
CELL METABOLISM Autophagy transcribed
Carmine Settembre et al.
NATURE (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Functional expression of TLR9 in esophageal cancer
Yanli Zhang et al.
ONCOLOGY REPORTS (2014)
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Elisavet Paplomata et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Jie Lin et al.
CLINICAL CANCER RESEARCH (2013)
Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
Yibing Yan et al.
CLINICAL CANCER RESEARCH (2013)
High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer
Hong Zhao et al.
MEDICAL ONCOLOGY (2013)
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
F. Bruzzese et al.
CELL DEATH & DISEASE (2013)
Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001
Christian R. Loehberg et al.
BIOCHEMICAL PHARMACOLOGY (2012)
A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB
Carmine Settembre et al.
EMBO JOURNAL (2012)
Autophagy and cancer
Kyeong Sook Choi
EXPERIMENTAL AND MOLECULAR MEDICINE (2012)
Identification of Anti-Malarial Compounds as Novel Antagonists to Chemokine Receptor CXCR4 in Pancreatic Cancer Cells
Joseph Kim et al.
PLOS ONE (2012)
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Joungmok Kim et al.
NATURE CELL BIOLOGY (2011)
HIF-1: upstream and downstream of cancer metabolism
Gregg L. Semenza
CURRENT OPINION IN GENETICS & DEVELOPMENT (2010)
In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Klaus P. Hoeflich et al.
CLINICAL CANCER RESEARCH (2009)
The role of autophagy in mammalian development: Cell makeover rather than cell death
Francesco Cecconi et al.
DEVELOPMENTAL CELL (2008)
Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
Qing-Bai She et al.
PLOS ONE (2008)
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis
Kurt Degenhardt et al.
CANCER CELL (2006)
Subversion of cellular autophagosomal machinery by RNA viruses
WT Jackson et al.
PLOS BIOLOGY (2005)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer
J Overgaard et al.
ACTA ONCOLOGICA (2000)
Share Paper
